Site Search
410 result(s) found for “ adaptive therapy”
-
Researchers Pinpoint Why Lymphoma Patients May Become Resistant to Specific Therapy, Identify Strategy to Overcome It
Loss of the BCL-2 amplicon and transcriptional reprogramming contribute to resistance to the drug Venetoclax® for those with B-cell lymphomas
-
Advancing Endometrial Cancer Treatment with Targeted Therapies
In June, the FDA approved the use of Durvalumab with carboplatin plus paclitaxel followed by single-agent durvalumab for patients with primary...
-
Eyeing New Therapies for Metastatic Uveal Melanoma
New $3.95 million multicenter grant will help researchers better understand the rare ocular cancer
-
Adoptive Cell Therapy Plus Checkpoint Inhibitors Show Promise in Non-Small Cell Lung Cancer
Moffitt-initiated pilot study finds patients with checkpoint inhibitor resistant tumors are responding to tumor infiltrating lymphocyte treatment
-
Investigational Combo Therapy Shows Benefit for TP53 Mutant MDS and Acute Myeloid Leukemia Patients
Trial results show eprenetapopt plus azacitidine improves response
-
Radiation Therapy May Boost Effectiveness of CAR T-Cell Treatment in Aggressive Multiple Myeloma
Moffitt study highlights the potential for improved outcomes by targeting extramedullary disease before cell therapy
-
21MA021N p53: Combination Therapy of Hypothermia and Chemotherapy to Treat Temperature Sensitive p53 Mutant Tumors
Combination Therapy of Hypothermia and Chemotherapy to Treat Temperatu FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICEThe...
-
Breakthrough Treatment for Small Cell Lung Cancer: New Therapy Offers Hope for Advanced-Stage Patients
Moffitt Cancer Center is proud to be the first institution in the United States to offer tarlatamab as a standard treatment for patients with...
-
Moffitt Plays Pivotal Role in FDA Approval of Tumor-Infiltrating Lymphocyte Therapy for Advanced Melanoma
The first-of-its-kind cellular immunotherapy uses the patient’s immune cells to seek out and kill their cancer
-
Novel Immunotherapy Trial using Chimeric Antigen Receptor Therapy (CAR T) for Relapsed Epithelial Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a CAR T designed to treat women with relapsed...